GTF3C5

Summary

GTF3C5 (general transcription factor IIIC subunit 5, HGNC:4668) is a protein-coding gene on chromosome 9q34.13, encoding General transcription factor 3C polypeptide 5 (Q9Y5Q8). Involved in RNA polymerase III-mediated transcription. It is a selective cancer dependency (DepMap: 68.9% of cell lines).

Enables RNA polymerase III general transcription initiation factor activity. Predicted to be involved in 5S class rRNA transcription by RNA polymerase III and tRNA transcription by RNA polymerase III. Predicted to act upstream of or within skeletal muscle cell differentiation. Located in nucleoplasm. Part of transcription factor TFIIIC complex.

Source: NCBI Gene 9328 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 1
• Clinical variants (ClinVar): 115 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 68.9% of screened cell lines
• MANE Select transcript: NM_012087

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4668
Approved symbol	GTF3C5
Name	general transcription factor IIIC subunit 5
Location	9q34.13
Locus type	gene with protein product
Status	Approved
Aliases	TFiiiC2-63, TFIIIC63, TFIIICepsilon
Ensembl gene	ENSG00000148308
Ensembl biotype	protein_coding
OMIM	604890
Entrez	9328

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 13 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000342018, ENST00000372097, ENST00000372099, ENST00000372108, ENST00000435745, ENST00000439697, ENST00000440319, ENST00000461871, ENST00000485692, ENST00000489842, ENST00000902265, ENST00000902266, ENST00000916423, ENST00000916424, ENST00000916425, ENST00000916426

RefSeq mRNA: 3 — MANE Select: NM_012087 NM_001122823, NM_001286709, NM_012087

CCDS: CCDS48050, CCDS6958, CCDS75927

Canonical transcript exons

ENST00000372097 — 11 exons

Exon	Start	End
ENSE00001372100	133050783	133050978
ENSE00001645855	133053828	133053942
ENSE00001803354	133030997	133031164
ENSE00001874074	133057814	133058503
ENSE00003257514	133042087	133042306
ENSE00003316805	133056012	133056094
ENSE00003494071	133043728	133043926
ENSE00003517680	133056766	133056908
ENSE00003517691	133054712	133054809
ENSE00003522629	133054408	133054488
ENSE00003789769	133052060	133052164

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 97.84.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 46.8763 / max 366.2142, expressed in 1823 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
99190	24.6824	1807
99188	16.9363	1797
99189	5.2576	1681

Top tissues by expression

274 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	97.84	gold quality
cerebellar hemisphere	UBERON:0002245	97.72	gold quality
cerebellar cortex	UBERON:0002129	97.61	gold quality
right uterine tube	UBERON:0001302	97.55	gold quality
left ovary	UBERON:0002119	96.96	gold quality
apex of heart	UBERON:0002098	96.63	gold quality
adenohypophysis	UBERON:0002196	96.59	gold quality
right ovary	UBERON:0002118	96.48	gold quality
lower esophagus mucosa	UBERON:0035834	96.32	gold quality
body of uterus	UBERON:0009853	96.03	gold quality
endocervix	UBERON:0000458	95.90	gold quality
cerebellum	UBERON:0002037	95.88	gold quality
pituitary gland	UBERON:0000007	95.86	gold quality
tibial nerve	UBERON:0001323	95.60	gold quality
ectocervix	UBERON:0012249	95.58	gold quality
skin of leg	UBERON:0001511	95.51	gold quality
granulocyte	CL:0000094	95.50	gold quality
skin of abdomen	UBERON:0001416	95.48	gold quality
left uterine tube	UBERON:0001303	95.43	gold quality
right lobe of thyroid gland	UBERON:0001119	95.34	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.14	gold quality
right testis	UBERON:0004534	95.05	gold quality
left testis	UBERON:0004533	94.95	gold quality
left lobe of thyroid gland	UBERON:0001120	94.84	gold quality
right adrenal gland	UBERON:0001233	94.78	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.78	gold quality
right adrenal gland cortex	UBERON:0035827	94.74	gold quality
muscle layer of sigmoid colon	UBERON:0035805	94.70	gold quality
ganglionic eminence	UBERON:0004023	94.65	gold quality
minor salivary gland	UBERON:0001830	94.64	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.65

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

15 targeting GTF3C5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4713-3P	100.00	65.92	505
HSA-MIR-12121	99.99	66.64	255
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-8080	99.82	67.52	1342
HSA-MIR-6745	99.74	65.33	1321
HSA-MIR-29B-1-5P	98.86	68.35	1364
HSA-MIR-6889-3P	98.84	67.35	1198
HSA-MIR-6529-3P	98.68	66.76	1020
HSA-MIR-4483	98.09	64.12	1642
HSA-MIR-6870-3P	98.08	65.10	692
HSA-MIR-450A-2-3P	97.91	67.56	1459
HSA-MIR-450B-3P	97.56	66.12	512
HSA-MIR-4793-5P	96.88	65.90	872
HSA-MIR-582-3P	96.69	67.38	1019
HSA-MIR-1293	96.16	64.69	916

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 68.9% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 1)

• Biallelic variants in GTF3C5, a regulator of RNA polymerase III-mediated transcription, cause a multisystem developmental disorder. (PMID:38520561)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	gtf3c5	ENSDARG00000067979
mus_musculus	Gtf3c5	ENSMUSG00000026816
rattus_norvegicus	Gtf3c5	ENSRNOG00000010981
drosophila_melanogaster	l(2)37Cd	FBGN0086445
caenorhabditis_elegans		WBGENE00011368

Protein

Protein identifiers

General transcription factor 3C polypeptide 5 — Q9Y5Q8 (reviewed: Q9Y5Q8)

Alternative names: TF3C-epsilon, Transcription factor IIIC 63 kDa subunit, Transcription factor IIIC subunit epsilon

All UniProt accessions (6): Q9Y5Q8, H0Y5D2, H7BY84, Q5T7U0, Q5T7U1, Q5T7U4

UniProt curated annotations — full annotation on UniProt →

Function. Involved in RNA polymerase III-mediated transcription. Integral, tightly associated component of the DNA-binding TFIIIC2 subcomplex that directly binds tRNA and virus-associated RNA promoters.

Subunit / interactions. Part of the TFIIIC subcomplex TFIIIC2, consisting of six subunits, GTF3C1, GTF3C2, GTF3C3, GTF3C4, GTF3C5 and GTF3C6. Interacts with BRF1, GTF3C6 and TBP.

Subcellular location. Nucleus.

Similarity. Belongs to the TFIIIC subunit 5 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9Y5Q8-1	1	yes
Q9Y5Q8-2	2
Q9Y5Q8-3	3

RefSeq proteins (3): NP_001116295, NP_001273638, NP_036219* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019136	TF_IIIC_su-5_HTH	Domain
IPR040454	TF_IIIC_Tfc1/Sfc1	Family
IPR041499	Tfc1/Sfc1_N	Domain
IPR042536	TFIIIC_tauA_Sfc1	Homologous_superfamily

Pfam: PF09734, PF17682

UniProt features (11 total): sequence conflict 2, compositionally biased region 2, splice variant 2, initiator methionine 1, chain 1, region of interest 1, modified residue 1, sequence variant 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
9GI4	X-RAY DIFFRACTION	2.63
8CLK	ELECTRON MICROSCOPY	3.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y5Q8-F1	78.37	0.48

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-749476	RNA Polymerase III Abortive And Retractive Initiation
R-HSA-76061	RNA Polymerase III Transcription Initiation From Type 1 Promoter
R-HSA-76066	RNA Polymerase III Transcription Initiation From Type 2 Promoter
R-HSA-74158	RNA Polymerase III Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-76046	RNA Polymerase III Transcription Initiation

MSigDB gene sets: 131 (showing top): GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_TRNA_METABOLIC_PROCESS, GOBP_TRANSCRIPTION_BY_RNA_POLYMERASE_III, GOBP_RRNA_TRANSCRIPTION, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, GOBP_SKELETAL_MUSCLE_ORGAN_DEVELOPMENT, GOBP_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GOBP_SKELETAL_MUSCLE_CELL_DIFFERENTIATION, DANG_BOUND_BY_MYC, GOCC_TRANSCRIPTION_REGULATOR_COMPLEX, BENPORATH_MYC_MAX_TARGETS, BIOCARTA_RNAPOL3_PATHWAY, GOBP_TRANSCRIPTION_INITIATION_AT_RNA_POLYMERASE_III_PROMOTER, GOBP_TRNA_TRANSCRIPTION, KOINUMA_TARGETS_OF_SMAD2_OR_SMAD3

GO Biological Process (5): transcription by RNA polymerase III (GO:0006383), transcription initiation at RNA polymerase III promoter (GO:0006384), skeletal muscle cell differentiation (GO:0035914), 5S class rRNA transcription by RNA polymerase III (GO:0042791), tRNA transcription by RNA polymerase III (GO:0042797)

GO Molecular Function (5): RNA polymerase III general transcription initiation factor activity (GO:0000995), DNA binding (GO:0003677), RNA polymerase III type 1 promoter sequence-specific DNA binding (GO:0001002), RNA polymerase III type 2 promoter sequence-specific DNA binding (GO:0001003), protein binding (GO:0005515)

GO Cellular Component (3): transcription factor TFIIIC complex (GO:0000127), nucleoplasm (GO:0005654), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
RNA Polymerase III Transcription	2
RNA Polymerase III Transcription Initiation	2
Gene expression (Transcription)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase III	4
RNA polymerase III cis-regulatory region sequence-specific DNA binding	2
DNA-templated transcription	1
DNA-templated transcription initiation	1
skeletal muscle tissue development	1
cell differentiation	1
rRNA transcription	1
tRNA transcription	1
general transcription initiation factor activity	1
nucleic acid binding	1
5S rDNA binding	1
binding	1
RNA polymerase III transcription regulator complex	1
nuclear lumen	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1552 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GTF3C5	GTF3C4	Q9UKN8	987
GTF3C5	GTF3C3	Q9Y5Q9	976
GTF3C5	GTF3C6	Q969F1	973
GTF3C5	GTF3C1	Q12789	955
GTF3C5	BRF1	Q92994	890
GTF3C5	GTF3C2	Q8WUA4	779
GTF3C5	BDP1	A6H8Y1	709
GTF3C5	POLR3G	O15318	570
GTF3C5	POLR3D	P05423	561
GTF3C5	POLR3A	O14802	546
GTF3C5	TCF7	P36402	545
GTF3C5	OR5B12	Q96R08	540
GTF3C5	GOLGA6L1	Q8N7Z2	501
GTF3C5	GOLGA8O	A6NCC3	474
GTF3C5	GOLGA8Q	H3BV12	448

IntAct

156 interactions, top by confidence:

A	B	Type	Score
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
FBL	NOP56	psi-mi:“MI:0914”(association)	0.800
PLK1	SPAG9	psi-mi:“MI:0914”(association)	0.790
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
GTF3C1	GTF3C2	psi-mi:“MI:0914”(association)	0.670
GTF3C3	POLR3D	psi-mi:“MI:0914”(association)	0.640
	GTF3C5	psi-mi:“MI:0915”(physical association)	0.560
KRT40	GTF3C5	psi-mi:“MI:0915”(physical association)	0.560
NOTCH2NLA	GTF3C5	psi-mi:“MI:0915”(physical association)	0.560
GTF3C5	MDFI	psi-mi:“MI:0915”(physical association)	0.560
GTF3C5	KRT40	psi-mi:“MI:0915”(physical association)	0.560
GTF3C5	NOTCH2NLA	psi-mi:“MI:0915”(physical association)	0.560
MDFI	GTF3C5	psi-mi:“MI:0915”(physical association)	0.560
GTF3C5		psi-mi:“MI:0915”(physical association)	0.560
KRTAP12-3	GTF3C5	psi-mi:“MI:0915”(physical association)	0.560
PLK1	C1orf226	psi-mi:“MI:0914”(association)	0.560
PRKCZ	IPO5	psi-mi:“MI:0914”(association)	0.530
ZNF764	IPO8	psi-mi:“MI:0914”(association)	0.530
FBL	ZNF316	psi-mi:“MI:0914”(association)	0.530
GTF3C6	GTF3C5	psi-mi:“MI:0915”(physical association)	0.500
ESR2	FBLL1	psi-mi:“MI:0914”(association)	0.460

BioGRID (225): GTF3C5 (Two-hybrid), KRT40 (Two-hybrid), KRTAP10-3 (Two-hybrid), NOTCH2NL (Two-hybrid), GTF3C5 (Affinity Capture-MS), GTF3C5 (Affinity Capture-MS), GTF3C5 (Affinity Capture-MS), BRD7 (Co-fractionation), GTF3C5 (Co-fractionation), GTF3C5 (Co-fractionation), PBRM1 (Co-fractionation), GTF3C5 (Affinity Capture-MS), GTF3C5 (Affinity Capture-MS), GTF3C5 (Affinity Capture-MS), GTF3C5 (Affinity Capture-MS)

ESM2 similar proteins: A6H7A8, A9X1A9, O75380, P05423, P82675, P82917, P82918, P82919, Q08BI9, Q0MQH6, Q0MQH7, Q1XHY1, Q2KID9, Q2NL14, Q2TBK2, Q4R5X8, Q4VA36, Q5E9Z7, Q5R595, Q5TM62, Q641X9, Q6ZWB6, Q767K8, Q80U62, Q86UT8, Q8CID0, Q8K2I9, Q8NFZ0, Q8R2L5, Q8VDD9, Q8WWQ0, Q91WD1, Q92622, Q99LB0, Q99N84, Q99N85, Q99N87, Q99N94, Q9BYC8, Q9BYD2

Diamond homologs: P32367, Q8R2T8, Q9Y5Q8

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
GTF3C5	“form complex”	TFIIIC	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 186 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RNA Polymerase III Transcription Initiation From Type 1 Promoter	7	23.2×	3e-06
RNA Polymerase III Transcription	8	21.2×	2e-06
RNA Polymerase III Transcription Initiation From Type 2 Promoter	6	20.6×	4e-05
RNA Polymerase III Transcription Initiation	7	19.1×	1e-05
RNA Polymerase III Abortive And Retractive Initiation	8	18.1×	3e-06
SARS-CoV-1 modulates host translation machinery	5	12.6×	2e-03
SPOP-mediated proteasomal degradation of PD-L1(CD274)	6	11.1×	1e-03
mRNA 3’-end processing	6	9.6×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
transcription by RNA polymerase III	6	28.6×	2e-05
mRNA splicing, via spliceosome	11	6.3×	4e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

115 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	94
Likely benign	9
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1724 predictions. Top by Δscore:

Variant	Effect	Δscore
9:133031150:G:GT	donor_gain	1.0000
9:133042200:G:GT	donor_gain	1.0000
9:133043724:CTAG:C	acceptor_loss	1.0000
9:133043725:TA:T	acceptor_loss	1.0000
9:133043726:A:AC	acceptor_loss	1.0000
9:133043726:A:AG	acceptor_gain	1.0000
9:133043726:AG:A	acceptor_gain	1.0000
9:133043726:AGG:A	acceptor_gain	1.0000
9:133043727:G:GG	acceptor_gain	1.0000
9:133043727:GG:G	acceptor_gain	1.0000
9:133043727:GGG:G	acceptor_gain	1.0000
9:133043727:GGGA:G	acceptor_gain	1.0000
9:133043727:GGGAT:G	acceptor_gain	1.0000
9:133043923:ACCG:A	donor_gain	1.0000
9:133043924:CCG:C	donor_gain	1.0000
9:133043924:CCGG:C	donor_loss	1.0000
9:133043925:CGGTA:C	donor_loss	1.0000
9:133043926:GGTA:G	donor_loss	1.0000
9:133043927:G:A	donor_loss	1.0000
9:133043927:G:GG	donor_gain	1.0000
9:133043928:TAA:T	donor_loss	1.0000
9:133050781:A:AG	acceptor_gain	1.0000
9:133050782:G:GG	acceptor_gain	1.0000
9:133050782:GGGAA:G	acceptor_gain	1.0000
9:133050928:A:T	donor_gain	1.0000
9:133050955:A:T	donor_gain	1.0000
9:133050964:G:GT	donor_gain	1.0000
9:133050967:GAGC:G	donor_gain	1.0000
9:133050970:C:G	donor_gain	1.0000
9:133050975:G:GT	donor_gain	1.0000

AlphaMissense

3412 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:133053840:T:A	W296R	1.000
9:133053840:T:C	W296R	1.000
9:133053835:G:A	G294D	0.999
9:133053844:G:C	R297P	0.999
9:133053852:T:A	W300R	0.999
9:133053852:T:C	W300R	0.999
9:133053918:C:G	R322G	0.999
9:133053919:G:C	R322P	0.999
9:133056858:G:T	R448M	0.999
9:133050844:C:A	R212S	0.998
9:133052081:T:A	W264R	0.998
9:133052081:T:C	W264R	0.998
9:133052097:T:A	V269D	0.998
9:133052154:C:A	A288D	0.998
9:133053834:G:C	G294R	0.998
9:133053843:C:A	R297S	0.998
9:133053850:T:C	L299P	0.998
9:133053910:T:C	L319P	0.998
9:133053912:G:C	D320H	0.998
9:133056825:G:A	G437E	0.998
9:133056827:T:A	W438R	0.998
9:133056827:T:C	W438R	0.998
9:133056858:G:C	R448T	0.998
9:133056859:G:C	R448S	0.998
9:133056859:G:T	R448S	0.998
9:133042118:T:C	L62P	0.997
9:133043874:T:C	S174P	0.997
9:133050837:A:C	R209S	0.997
9:133050837:A:T	R209S	0.997
9:133052073:G:C	R261P	0.997

dbSNP variants (sampled 300 via entrez): RS1000082477 (9:133047802 G>A), RS1000115125 (9:133047574 T>G), RS1000258627 (9:133042805 G>A), RS1000282782 (9:133047694 G>A), RS1000362483 (9:133031535 A>G), RS1000375059 (9:133042616 CA>C), RS1000426536 (9:133042448 C>T), RS1000748646 (9:133031866 GT>G), RS1000775861 (9:133031228 A>G), RS1000939749 (9:133051402 G>A), RS1000951021 (9:133057439 A>C,G), RS1001101162 (9:133033168 A>T), RS1001158460 (9:133037608 A>G), RS1001198542 (9:133031951 G>A,C), RS1001257910 (9:133037680 G>A,T)

Disease associations

OMIM: gene MIM:604890 | disease phenotypes: MIM:191100, MIM:619424

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Strong	Autosomal recessive
complex neurodevelopmental disorder	Moderate	Autosomal recessive

Mondo (4): tuberous sclerosis 1 (MONDO:0008612), myopathy, myofibrillar, 12, infantile-onset, with cardiomyopathy (MONDO:0859168), complex neurodevelopmental disorder (MONDO:0100038), neurodevelopmental disorder (MONDO:0700092)

Orphanet (1): Tuberous sclerosis complex (Orphanet:805)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST011595_6	Sepsis (28-day mortality)	3.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004352	mortality

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625
C565346	Tuberous Sclerosis 1 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067392 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, decreases expression, increases abundance	3
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
lead acetate	decreases expression, affects cotreatment	1
beta-lapachone	increases expression	1
ochratoxin A	decreases expression	1
2,3,5-(triglutathion-S-yl)hydroquinone	increases ADP-ribosylation	1
AM 251	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
clothianidin	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
Acetaminophen	increases expression	1
Arsenic	decreases expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Caffeine	decreases phosphorylation	1
Cisplatin	increases expression	1
Ivermectin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Valproic Acid	increases methylation	1
Vanadates	decreases expression	1
Okadaic Acid	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651518	Binding	Binding affinity to human GTF3C5 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

3 cell lines: 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A2J6	SEES3-1V human GTF3C5, clone1	Embryonic stem cell	Male
CVCL_A2J7	SEES3-1V human GTF3C5, clone2	Embryonic stem cell	Male
CVCL_A2J8	SEES3-1V human GTF3C5, clone3	Embryonic stem cell	Male

Clinical trials (associated diseases)

208 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT02201212	PHASE2	COMPLETED	Everolimus for Cancer With TSC1 or TSC2 Mutation
NCT05103358	PHASE2	ACTIVE_NOT_RECRUITING	Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase